Our previous studies from both preclinical and clinical researches also demonstrated their effects in improving ischemia‐type biliary lesion after LT and attenuating liver IRI.[8, 40] In the present study, we additionally found that accompanied by the recovery of liver function and liver pathological changes in the IRI model, UC‐MSCs could not only reduce the levels of serological pro‐inflammatory cytokines (IL‐6, TNF‐α and IFN‐γ), but also suppress membranous CD154 expression of the intrahepatic CD4+ T cells. The gene discussed is CD40LG; the disease is ischemia.